Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
Breakthroughs in Bladder Cancer Treatments at ASCO GU
Merck unveiled promising bladder cancer treatments at the 2026 ASCO Genitourinary (GU) Cancers Symposium, showcasing data from its portfolio including KEYTRUDA® (pembrolizuma...
Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões
Robotic Surgery Portugal Achieves Historic First at ULS Viseu Dão-Lafões
Robotic surgery Portugal has reached a new milestone with the successful first procedure at the Local Health Unit (ULS) Viseu Dão-Lafões...
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa
Pharmaceutical Tender Investigation Targets Ascendis, Pharma Q, and Sonke
The Competition Commission of South Africa has launched a pharmaceutical tender investigation into manufacturers Ascendis, Pharma Q, and...